Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone

2013 ◽  
Vol 25 (2) ◽  
pp. 119-121 ◽  
Author(s):  
Enrica Di Rosa ◽  
Daniela Caldirola ◽  
Achille Motta ◽  
Giampaolo Perna

ObjectiveUrgency, urinary incontinence and bowel disturbances are distressing side effects that have been observed during treatment with risperidone and other antipsychotics probably due to the receptor affinity profile. This occurrence can lead to poor compliance and therefore impair clinical outcome.MethodWe report the case of a 50 year‐old lady, who experienced urinary incontinence and diarrhoea, when switching from oral to injectable risperidone, which ceased when discontinuing the drug.Results and conclusionsIt should be taken into account that some side effects can be revealed when switching from oral to depot formulations due to non‐compliance to orals; nevertheless dose‐dependent mechanisms and individual metabolic variability must be considered when observing idiosyncratic reactions to drugs.

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Nitya Abraham ◽  
Iryna Makovey ◽  
Ashley King ◽  
Howard Goldman ◽  
Sandip Vasavada

1985 ◽  
Vol 110 (4) ◽  
pp. 433-439 ◽  
Author(s):  
D. Dewailly ◽  
P. Thomas ◽  
J. Buvat ◽  
J. L. Wemeau ◽  
J. C. Fourlinnie ◽  
...  

Abstract. CU 38085 (mesulergin) was given at doses ranging from 0.5 to 5 mg/day to 37 patients with pathological hyperprolactinaemia of varying aetiology. The effectiveness of this drug on the suppression of hyperprolactinaemia and on the recovery of gonadal functions was equivalent to that of bromocriptine previously given to a different group of 83 hyperprolactinaemic patients. Tumour shrinkage during treatment with CU 32085 was ascertained in two cases of macroprolactinoma. Histological examination after adenomectomy revealed extensive peri-vascular fibrosis in both cases. In most patients, the efficient doses of CU 32085 were 5-fold lower than those of bromocriptine. After acute oral administration in 10 previously untreated patients, 0.5 mg of CU 32085 had a more prolonged suppressive effect on Prl levels than 2.5 mg of bromocriptine (approximately 18 vs 12 h). According to this, 0.5 mg CU 32085 once a day was sufficient to maintain Prl levels within the normal range in 16 patients. Side-effects were similar in nature and frequency to those induced by bromocriptine and seemed to be dose-dependent. They can be avoided by slowly increases of dose at initiation of treatment.


2021 ◽  
Vol 28 (1) ◽  
pp. 17-24
Author(s):  
Mariana Mihaĺová ◽  
Magdaléna Hagovská ◽  
Katarína Oravcová ◽  
Ján Švihra

Sign in / Sign up

Export Citation Format

Share Document